Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy
Read More Pharma Industry News Rhythm Pharmaceuticals (RYTM) surges 35% after announcing Phase 2 trial data reveal for oral MC4R agonist bivamelagon Find out why Rhythm Pharmaceuticals stock surged over 35% and what the upcoming bivamelagon trial results mean for its rare disease pipeline. byPallavi MadhirajuJuly 9, 2025